PROSTVAC

PROSTVAC is Bavarian Nordic’s lead targeted immunotherapy candidate that is being investigated for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Encouraging results from the PROSTVAC development program are being validated with the ongoing pivotal phase 3 PROSPECT study, conducted in collaboration with the National Cancer Institute under a Special Protocol Assessment from the US Food and Drug Administration (FDA). Data to date also suggest that PROSTVAC has potential in combination with other therapies and/or in earlier stages of the disease.

Read more